Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Epigenetic control of group V phospholipase A2 expression in human malignant cells

Authors: Mario Menschikowski, Albert Hagelgans, Brit Nacke, Carsten Jandeck, Olga A. Mareninova, Liana Asatryan, Gabriele Siegert

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Secreted phospholipases A2 (sPLA2) are suggested to play an important role in inflammation and tumorigenesis. Different mechanisms of epigenetic regulation are involved in the control of group IIA, III and X sPLA2s expression in cancer cells, but group V sPLA2 (GV-PLA2) in this respect has not been studied. Here, we demonstrate the role of epigenetic mechanisms in regulation of GV-PLA2 expression in different cell lines originating from leukaemia and solid cancers. In blood leukocytes from leukaemic patients, levels of GV-PLA2 transcripts were significantly lower in comparison to those from healthy individuals. Similarly, in DU-145 and PC-3 prostate and CAL-51 and MCF-7 mammary cancer cell lines, levels of GV-PLA2 transcripts were significantly lower in relation to those found in normal epithelial cells of prostate or mammary. By sequencing and methylation-specific high-resolution melting (MS-HRM) analyses of bisulphite-modified DNA, distinct CpG sites in the GV-PLA2 promoter region were identified that were differentially methylated in cancer cells in comparison to normal epithelial and endothelial cells. Spearman rank order analysis revealed a significant negative correlation between the methylation degree and the cellular expression of GV-PLA2 (r = −0.697; p = 0.01). The effects of demethylating agent (5-aza-2′-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) on GV-PLA2 transcription in the analysed cells confirmed the importance of DNA methylation and histone modification in the regulation of the GV-PLA2 gene expression in leukaemic, prostate and mammary cancer cell lines. The exposure of tumour cells to human recombinant GV-PLA2 resulted in a reduced colony forming activity of MCF-7, HepG2 and PC-3 cells, but not of DU-145 cells suggesting a cell-type-dependent effect of GV-PLA2 on cell growth. In conclusion, our results suggest that epigenetic mechanisms such as DNA methylation and histone modification play an important role in downregulation of GV-PLA2 expression in cancer cells.
Appendix
Available only for authorised users
Literature
1.
2.
Murakami M, Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: an update. Biochimie. 2013;95:43–50.CrossRefPubMed
3.
Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 2006;79:1–33.CrossRefPubMed
4.
Chen J, Engle SJ, Seilhamer JJ, Tischfield JA. Cloning and recombinant expression of a novel human low molecular weight Ca2+-dependent phospholipase A2. J Biol Chem. 1994;269:2365–8.PubMed
5.
Xue M, Shen K, McKelvey K, Li J, Chan YK, Hatzis V, et al. Endothelial protein C receptor associated invasiveness of rheumatoid synovial fibroblasts is likely driven by group V secretory phospholipase A2. Arthritis Res Ther. 2014;16:R44.CrossRefPubMedPubMedCentral
6.
Rosengren B, Peilot H, Umaerus M, Jönsson-Rylander AC, Mattsson-Hultén L, Hallberg C, et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol. 2006;26:1579–85.CrossRefPubMed
7.
Sonoki K, Iwase M, Ohdo S, Ieiri I, Matsuyama N, Takata Y, et al. Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity. J Cardiovasc Pharmacol. 2012;60:367–74.CrossRefPubMed
8.
Muñoz NM, Desai A, Meliton LN, Meliton AY, Zhou T, Leff AR, et al. Group V phospholipase A2 increases pulmonary endothelial permeability through direct hydrolysis of the cell membrane. Pulm Circ. 2012;2:182–92.CrossRefPubMedPubMedCentral
9.
Rosenson RS, Gelb MH. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr Cardiol Rep. 2009;11:445–51.CrossRefPubMed
10.
Balestrieri B, Arm JP. Group V sPLA2: classical and novel functions. Biochim Biophys Acta. 2006;1761:1280–8.CrossRefPubMed
11.
Degousee N, Ghomashchi F, Stefanski E, Singer A, Smart BP, Borregaard N, et al. V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem. 2002;277:5061–73.CrossRefPubMed
12.
Kim KP, Rafter JD, Bittova L, Han SK, Snitko Y, Munoz NM, et al. Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J Biol Chem. 2001;276:11126–34.CrossRefPubMed
13.
Rubio JM, Rodríguez JP, Gil-de-Gómez L, Guijas C, Balboa MA, Balsinde J. Group V Secreted Phospholipase A2 Is Upregulated by IL-4 in Human Macrophages and Mediates Phagocytosis via Hydrolysis of Ethanolamine Phospholipids. J Immunol. 2015;194:3327–39.CrossRefPubMed
14.
Boilard E, Lai Y, Larabee K, Balestrieri B, Ghomashchi F, Fujioka D, et al. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med. 2010;2:172–87.CrossRefPubMedPubMedCentral
15.
Murakami M, Sato H, Miki Y, Yamamoto K, Taketomi Y. A New Era of Secreted Phospholipase A2 (sPLA2). J Lipid Res. 2015;56:1248–61.PubMedPubMedCentral
16.
Ito M, Ishikawa Y, Kiguchi H, Komiyama K, Murakami M, Kudo I, et al. Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease. J Gastroenterol Hepatol. 2004;19:1140–9.CrossRefPubMed
17.
Masuda S, Murakami M, Ishikawa Y, Ishii T, Kudo I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim Biophys Acta. 2005;1736:200–10.CrossRefPubMed
18.
Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie. 2010;92:601–10.CrossRefPubMed
19.
Quach ND, Arnold RD, Cummings BS. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol. 2014;90:338–48.CrossRefPubMedPubMedCentral
20.
Brglez V, Lambeau G, Petan T. Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie. 2014;107:114–23.CrossRefPubMed
21.
Mounier CM, Wendum D, Greenspan E, Fléjou JF, Rosenberg DW, Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer. 2008;98:587–95.CrossRefPubMedPubMedCentral
22.
Fiancette R, Vincent C, Donnard M, Bordessoule D, Turlure P, Trimoreau F, et al. Genes encoding multiple forms of phospholipase A2 are expressed in immature forms of human leukemic blasts. Leukemia. 2009;23:1196–9.CrossRefPubMed
23.
Menschikowski M, Hagelgans A, Kostka H, Eisenhofer G, Siegert G. Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells. Neoplasia. 2008;10:1195–203.CrossRefPubMedPubMedCentral
24.
Gorovetz M, Baekelandt M, Berner A, Trope’ CG, Davidson B, Reich R. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol. 2006;103:831–40.CrossRefPubMed
25.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54.CrossRefPubMed
26.
Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. 2014;455:43–57.CrossRefPubMedPubMedCentral
27.
Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, Siegert G. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008;10:279–86.CrossRefPubMedPubMedCentral
28.
Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008;68:4277–86.CrossRefPubMed
29.
Brglez V, Pucer A, Pungerčar J, Lambeau G, Petan T. Secreted phospholipases A2 are differentially expressed and epigenetically silenced in human mammary cancer cells. Biochem Biophys Res Commun. 2014;445:230–5.CrossRefPubMed
30.
Lacroux C, Vilette D, Fernández-Borges N, Litaise C, Lugan S, Morel N, et al. Prionemia and leukocyte-platelet-associated infectivity in sheep transmissible spongiform encephalopathy models. J Virol. 2012;86:2056–66.CrossRefPubMedPubMedCentral
31.
McCurdy RD, McGrath JJ, Mackay-Sim A. Validation of the comparative quantification method of real-time PCR analysis and a cautionary tale of housekeeping gene selection. Gene Ther Mol Biol. 2008;12:15–24.
32.
Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–31.CrossRefPubMed
33.
Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31:3651–3.CrossRefPubMedPubMedCentral
34.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–80.CrossRefPubMedPubMedCentral
35.
Ben-Hattar J, Jiricny J. Methylation of single CpG dinucleotides within a promoter element of the Herpes simplex virus tk gene reduces its transcription in vivo. Gene. 1988;65:219–27.CrossRefPubMed
36.
Douet V, Heller MB, Le Saux O. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem Biophys Res Commun. 2007;354:66–71.CrossRefPubMed
37.
Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 2006;131:1835–43.CrossRefPubMed
38.
Miki Y, Mukae S, Murakami M, Ishikawa Y, Ishii T, Ohki H, et al. Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX-2. Anticancer Res. 2007;27:1493–502.PubMed
39.
Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245–54.CrossRefPubMed
40.
41.
Menschikowski M, Platzbecker U, Hagelgans A, Vogel M, Thiede C, Schönefeldt C, et al. Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells. BMC Cancer. 2012;12:576.CrossRefPubMedPubMedCentral
42.
Bernard D, Vindrieux D. PLA2R1: expression and function in cancer. Biochim Biophys Acta. 1846;2014:40–4.
43.
Surrel F, Jemel I, Boilard E, Bollinger JG, Payré C, Mounier CM, et al. Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators. Mol Pharmacol. 2009;76:778–90.CrossRefPubMedPubMedCentral
44.
Pucer A, Brglez V, Payré C, Pungerčar J, Lambeau G, Petan T. Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival. Mol Cancer. 2013;12:111.CrossRefPubMedPubMedCentral
45.
Martín R, Cordova C, Nieto ML. Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding. J Neuroinflammation. 2012;9:154.CrossRefPubMedPubMedCentral
46.
Henderson Jr WR, Ye X, Lai Y, Ni Z, Bollinger JG, Tien YT, et al. Key role of group V secreted phospholipase A2 in Th2 cytokine and dendritic cell-driven airway hyperresponsiveness and remodeling. PLoS One. 2013;8:e56172.CrossRefPubMed
47.
Murakami M, Kambe T, Shimbara S, Higashino K, Hanasaki K, Arita H, et al. Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J Biol Chem. 1999;274:31435–44.CrossRefPubMed
Metadata
Title
Epigenetic control of group V phospholipase A2 expression in human malignant cells
Authors
Mario Menschikowski
Albert Hagelgans
Brit Nacke
Carsten Jandeck
Olga A. Mareninova
Liana Asatryan
Gabriele Siegert
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4670-x

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Review

Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future

Original Article

MiR-130b inhibits proliferation and induces apoptosis of gastric cancer cells via CYLD

Original Article

Upregulation of connexin43 contributes to PX-12-induced oxidative cell death

Original Article

CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells

Original Article

Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer

Original Article

MiR-214 suppressed ovarian cancer and negatively regulated semaphorin 4D

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits